Teladoc Health (TDOC)
(Real Time Quote from BATS)
$10.10 USD
-0.10 (-0.98%)
Updated Jun 13, 2024 10:06 AM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
Price, Consensus and EPS Surprise
TDOC 10.10 -0.10(-0.98%)
Will TDOC be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TDOC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TDOC
Teladoc (TDOC) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Teladoc (TDOC) Stock Slides as Market Rises: Facts to Know Before You Trade
TDOC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elevance Health (ELV) Stock Jumps 6.1%: Will It Continue to Soar?
Teladoc (TDOC) Registers a Bigger Fall Than the Market: Important Facts to Note
Here is What to Know Beyond Why Teladoc Health, Inc. (TDOC) is a Trending Stock
Other News for TDOC
Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M
Teladoc’s Leadership Change and Strategy Review: A Hold Recommendation Amidst Uncertainty
Strategic CEO Appointment Bolsters Teladoc’s Market Leadership and Buy Rating
Truist Financial Sticks to Their Hold Rating for Teladoc (TDOC)
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC) and Dexcom (DXCM)